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173 Upper respiratory tract colonization in infants with cystic ﬁbrosis
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H. Wos1, B. Kordys-Darmolin´ska1, M. Sankiewicz-Szkolka2, U. Grzybowska-
Chlebowczyk1. 1Medical Silesian University, Pediatric Department, Katowice,
Poland; 2Uppersilesian Child Health Centre, Pediatric Department, Katowice,
Poland
Cystic ﬁbrosis, is characterised by production of abnormally thick and viscous
mucus. It results in disturbances of mucociliary clearance, a basic defensive
mechanism of the respiratory system, leading to increased susceptibility to recurrent
and chronic respiratory infections in over 90% of patients.
The aim of this study is to evaluate nasopharyngeal cavity colonization in infants
with cystic ﬁbrosis diagnosed by newborn screening.
Material and Methods: Nasal and pharyngeal swabs were obtained from 26 infants
aged 10−20 weeks, without any signs of infections, who were examined in the Cystic
Fibrosis Outpatient Clinic. Isolates were identiﬁed by means of routine diagnostic
methods.
Results: Negative nasal swabs were obtained in 10 (40%) infants, negative
pharyngeal swabs − in 6 (23%), and in 4 patients both nasal and pharyngeal
swabs were negative. In the nasal swabs the most frequently observed growths
were: Staphylococcus aureus MSSA(+) in 9 (34.5%), Corynebacterium sp. in 6
(23.5%), and b-lactamase(+) Moraxella catarrhalis in 2 (8%). Pharyngeal swabs
revealed a-hemolytic Streptococcus in 20 (80%), Staphylococcus aureus MRSA(+)
in 7 (27%), Neisseria sp. in 4 (15%), Escherichia coli ESBL(−) and Candida
albicans in 3 (11.5%) examined infants.
Conclusion: Nasopharyngeal cavity colonization by pathogenic bacteria in infants
suffering from cystic ﬁbrosis occurs during the ﬁrst months of life, in the absence
of noticeable signs of upper respiratory infection.
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Objective: Nasal polyposis (NP) is common in cystic ﬁbrosis. Some reports have
suggested that patients with NP have an improved pre-transplant survival. The
inﬂuence of the NP-phenotype (NPP) on survival and bronchiolitis obliterans
syndrome (BOS) after lung transplantation (LTx) is unknown.
Aim: To determine the prevalence of the NPP and its inﬂuence on survival and
BOS after LTx.
Methods: All CF patients transplanted at our center between Nov 92 and Dec 09
were included. Survival and BOS following LTx were compared in the NPP with
the non-NPP by Kaplan Meyer statistic.
Results: The 89 evaluated patients (44 females, 49%) had a mean age of
26.8±8.2 years at LTx, pre-LTx FEV1 of 1.0±1.8 liters (26±8%) and estimated
5-year survival without LTx of 33±14%. 17 (19%) patients had NP. No differ-
ence was found regarding gender, pretransplant FEV1, estimate survival without
LTx, pretransplant Pseudomonas infections, pretransplant prednisone treatment,
pretransplant diabetes and mutation on the CFTR-gene in the two phenotype.
Overall 1-, 5- and 10-years survival was 90±3%, 71±5%, 59±6%. One, 5- and 10-
years survival in the NP-phenotype was 94±6%, 77±10%, 61±13%, compared to
89±4%, 69±6%, 59±7%. No signiﬁcant difference was found in the development
of BOS in the two groups (freedom of BOS 1 at 5-year 88±7% in NP-phenotype
compared to 78±5%). However, there was a tendency of less BOS stage 1 in the
NP-phenotype.
Conclusions: In our cohort of CF patients with LTx nasal polyps are found in
one ﬁfth. Patients with nasal polyps have the same survival compared to non-NP
patients. There is a tendency of less BOS in patients with NP. This is probably a
speciﬁc ﬁnding for the NP-phenotype.
175 Sinonasal disease in adult CF patients: prevalence and
management in Wales
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The nasal and paranasal sinuses are contiguous with the lower respiratory tract. CF
patients commonly experience sinonasal disease which is thought to have the same
aetiology and pathophysiology as the chronic lung condition. Evidence suggests
that sinonasal disease may directly inﬂuence the lower airways in CF.
Purpose:
i. To identify the prevalence of adult CF patients with sinonasal disease in Wales
ii. To review assessment and treatment strategies used in patients with sinonasal
disease.
Method: A retrospective review of sinonasal disease was conducted. Data were
collected from annual assessments between 2010 and 2011. All patients had a
conﬁrmed diagnosis of CF and were under the care of the All Wales Adult CF
Centre. The following data were recorded: age; sex; FEV1; genotype; sputum
microbiology; sinonasal disease status (sinusitis or polyposis), sinonasal symptoms
(pain, congestion, discharge, postnasal drip); referrals and investigations (ENT, CT,
sinus sampling); medication; nasal washouts.
Results: 162 records were reviewed. Mean age 28 (17−53 yrs). 81 reported history
of sinonasal disease; 23 had both; 29 referred to ENT; of which 12 had polyps;
5 had sinus CT; 48 prescribed nasal steroid; 4 antibiotics; 28 antihistamine; 1
analgesia; 0 sympathomimetics, 3 nasal rinse and no patients underwent sinus
sampling. Severities of phenotype or FEV1 were not related to presence of sinonasal
disease in this group.
Conclusion: The prevalence of sinonasal disease in our centre appears signiﬁcantly
lower than previous studies. This service evaluation highlights the need for the
development of a protocol in the assessment and management of this patient group.
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Objectives: The diagnosis of ABPA in CF is hampered by both poorly standardised
diagnostic criteria and its often non-speciﬁc clinical presentation. The Cystic
Fibrosis Foundation consensus conference in 2003 produced minimum diagnostic
criteria for ABPA. There have been no randomised controlled trials of treatment in
CF but corticosteroids are usually prescribed, oral antifungals are often added. We
sought to determine our compliance with these minimum diagnostic criteria and
UK CF trust guidelines for treatment.
Methods: A retrospective case note review identiﬁed patients with a current or
prior ABPA diagnosis. Their diagnostic tests were compared to minimum criteria
and treatment regime recorded, 40 control patients without ABPA were compared.
Results: 10 of 132 patients (7.6%) had been given a diagnosis of ABPA. Only 3
met all 4 minimum criteria at the time of diagnosis, the remaining 7 met 2 or 3.
Five of the patients had a total serum IgE level >500 iu/ml. Mean values of total
IgE and Aspergillus speciﬁc IgE were signiﬁcantly higher in ABPA cases than the
40 controls but IgG precipitin titres were higher in the control group. The treatment
initiated was variable. All cases were prescribed steroids but dosage and duration
recommended was variable, 5 patients were started on anti-fungals.
Discussion: The diagnosis of ABPA in our centre seldom met minimum diagnostic
criteria and treatment regimes were variable. Our experience is unlikely to be
uncommon. This may arise due to poorly deﬁned UK diagnostic recommendations
and the lack of robust evidence to guide treatment. A new ABPA protocol has been
implemented in our centre to address these inconsistencies.
